Loading…
TransCode Therapeutics, Inc. is projected to decline to $8.27 by 2027, a -6% move from its current price of $8.83. RNAZ is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $8.13 | $8.83 | $9.60 | +0.04% |
| Jul 14 | $7.86 | $8.84 | $9.93 | +0.07% |
| Jul 15 | $7.66 | $8.84 | $10.20 | +0.11% |
| Jul 16 | $7.49 | $8.84 | $10.44 | +0.15% |
| Jul 17 | $7.35 | $8.85 | $10.65 | +0.18% |
| Jul 18 | $7.22 | $8.85 | $10.84 | +0.22% |
| Jul 19 | $7.11 | $8.85 | $11.02 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.11 | $8.85 | $11.02 | +0.26% |
| Week 2 | $6.51 | $8.88 | $12.10 | +0.51% |
| Week 3 | $6.09 | $8.90 | $13.01 | +0.77% |
| Week 4 | $5.76 | $8.92 | $13.83 | +1.03% |
| Week 5 | $5.48 | $8.94 | $14.60 | +1.29% |
| Week 6 | $5.24 | $8.97 | $15.34 | +1.55% |
| Week 7 | $5.03 | $8.99 | $16.05 | +1.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor.
The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center.
The company was incorporated in 2016 and is based in Boston, Massachusetts.
RNAZ is the stock symbol for TransCode Therapeutics, Inc. It trades with a current price of $8.83 and a market cap of $8.39M, ranking 5184 by market cap. The stock shows a bullish sentiment in its near-term technical picture, with a range of factors influencing the path forward.
The forecast provides a year-by-year view of potential price behavior, highlighting a mix of neutral, bearish, and bullish periods through 2050.
A major floor 70.4% below — a decisive break under it would weaken the trend.
The nearest floor, 48.5% below — buyers have tended to step in here.
The nearest ceiling, 8.7% above — a clean break opens room to run.
A major ceiling 43.9% above — clearing it would confirm fresh momentum.
Key RNAZ support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNAZ market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.50 | Buy | $8.51 | Buy |
| MA 10 | $7.52 | Buy | $7.75 | Buy |
| MA 20 | $6.33 | Buy | $6.94 | Buy |
| MA 50 | $6.35 | Buy | $6.77 | Buy |
| MA 100 | $7.74 | Buy | $7.82 | Buy |
| MA 200 | $8.84 | Sell | $290.61 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.59 | Neutral |
| Stoch RSI (14) | 74.66 | Neutral |
| CCI (20) | 115.25 | Buy |
| Williams %R (14) | -15.16 | Info |
| MACD (12,26,9) | 0.44 | Buy |
| ROC (12) | 81.87 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 84.84 | Sell |
| TRIX (15) | 0.72 | Buy |
| Awesome (5,34) | 2.54 | Buy |
| Ultimate (7,14,28) | 68.89 | Neutral |
| Momentum (10) | 4.28 | Buy |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 9.19 | Sell |
| ADX (14) | 28.94 | Buy |
| ATR (14) | 0.59 | Info |
The 30-day technical picture shows a bullish stance overall. The RSI(14) is 60, and the moving averages sit at SMA50 $6.35 and SMA200 $8.84, framing current momentum. Key support is placed at $4.55 and resistance at $9.60, with a 30-day price range from $5.12 to $15.24.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.55 | $8.83 | $10.99 | 0% | Neutral | |
| $6.00 | $8.27 | $12.32 | -6% | Neutral | |
| $4.64 | $6.80 | $10.80 | -23% | Bearish | |
| $4.68 | $7.23 | $12.05 | -18% | Bearish | |
| $4.16 | $6.72 | $11.67 | -24% | Bearish | |
| $4.02 | $6.79 | $12.19 | -23% | Bearish | |
| $5.88 | $10.36 | $19.19 | +17% | Neutral | |
| $5.91 | $10.85 | $20.66 | +23% | Bullish | |
| $5.11 | $9.77 | $19.07 | +11% | Neutral | |
| $4.87 | $9.68 | $19.33 | +10% | Neutral | |
| $6.82 | $15.15 | $33.25 | +72% | Bullish | |
| $8.31 | $18.46 | $42.45 | +109% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.55 | $8.83 | $10.60 | +0.00% |
| August 2026 | $7.18 | $8.69 | $10.97 | -1.53% |
| September 2026 | $7.43 | $9.13 | $11.76 | +5.01% |
| October 2026 | $7.19 | $8.94 | $11.71 | -2.09% |
| November 2026 | $6.58 | $8.27 | $10.99 | -7.50% |
| December 2026 | $6.43 | $8.16 | $10.99 | -1.33% |
Click any year to see its month-by-month RNAZ forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RNAZ is projected to trade between $4.55 and $10.99, averaging $8.83 — a potential gain of 0% from today's $8.83. Price action looks broadly range-bound.
TransCode Therapeutics, Inc.'s 2027 outlook centres on $8.27, within a $6.00 to $12.32 range. That is -6% versus the projected 2026 average. That marks a -6% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, RNAZ could reach as high as $10.80, with a base case around $6.80 and support toward $4.64 — roughly -23% from $8.83. A cyclical pullback looks likely — prices rarely move in a straight line.
Expect RNAZ to range from $4.68 to $12.05 through 2029. The $7.23 average target implies a -18% move from current prices. That is up +6% on the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
The RNAZ price prediction for 2030 points to an average of $6.72 (low $4.16, high $11.67) — a potential decline of -24% on today's $8.83. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2031, RNAZ is projected to trade between $4.02 and $12.19, averaging $6.79 — a potential decline of -23% from today's $8.83. That is up +1% on the projected 2030 average. Expect choppier, lower action through this leg of the cycle.
TransCode Therapeutics, Inc.'s 2032 outlook centres on $10.36, within a $5.88 to $19.19 range. That is up +53% on the projected 2031 average. That marks a +17% change versus current levels. Price action looks broadly range-bound.
By 2033, RNAZ could reach as high as $20.66, with a base case around $10.85 and support toward $5.91 — roughly +23% from $8.83. Buyers look set to stay in control over this stretch.
Expect RNAZ to range from $5.11 to $19.07 through 2034. The $9.77 average target implies a +11% move from current prices. That is -10% versus the projected 2033 average. Price action looks broadly range-bound.
The RNAZ price prediction for 2035 points to an average of $9.68 (low $4.87, high $19.33) — a potential gain of +10% on today's $8.83. A consolidation phase looks the most probable path here.
In 2040, RNAZ is projected to trade between $6.82 and $33.25, averaging $15.15 — a potential gain of +72% from today's $8.83. That is up +57% on the projected 2035 average. Momentum favours further upside here.
TransCode Therapeutics, Inc.'s 2050 outlook centres on $18.46, within a $8.31 to $42.45 range. That is up +22% on the projected 2040 average. That marks a +109% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in RNAZ today (≈ 113.250283 RNAZ) could be worth
$2,090.28
+$1,090.28 (+109%) by 2050 · US Dollar
Based on the average projected RNAZ price of $18.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNAZwould be worth at today's price.
$1,000 invested in RNAZ on Jul 10, 2025 (≈ 111.111111 RNAZ) would be worth
$981.11
-$18.89 (-1.9%) today · 0.98× · US Dollar
Based on a RNAZ entry price of $9 vs. today's $8.83.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.61 | $1,025.55 | +2.6% |
| 1 month ago | $5.51 | $1,602.54 | +60.3% |
| 3 months ago | $8.21 | $1,075.52 | +7.6% |
| 6 months ago | $7.95 | $1,110.69 | +11.1% |
| 1 year ago | $9 | $981.11 | -1.9% |
| All time (5.0y) ago | $3,370,752 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNAZ forecast.
Our base-case forecast reaches $18.00 around 2050.
Implied market cap at $18.00: $17.11M
The multi-year forecast presents a varied path. In 2026 the avg price is $8.83 with a neutral sentiment, while subsequent years slide into bearish territory through 2031. From 2032 the outlook turns neutral to bullish, with 2032 avg $10.36 and 2033 avg $10.85, and by 2040 the avg rises to $15.15 with a 71.5% return and bullish sentiment.
By 2050 the avg is $18.46 with a 109% return and bullish sentiment. These figures imply meaningful upside over the long run, but there are meaningful near-term risks and volatility that investors should consider.
Tap a question to reveal the answer.
2030 avg $6.72; min $4.16; max $11.67; roi -23.9%; sentiment BEARISH.
The forecast shows a neutral stance in 2026 (avg $8.83, roi 0%), followed by bearish years through 2031, then a shift toward bullish in 2032-2050, with 2050 avg $18.46 and roi 109%.
The forecast lists a max of $42.45 by 2050, not $50, with associated risks.
2040 avg $15.15 (71.5%), 2050 avg $18.46 (109%), bullish sentiment, with earlier years showing mixed to bearish momentum.
Current price is $8.83. Nearest support is $4.55 and nearest resistance is $9.60.
TransCode Therapeutics, Inc. Community Discussion
0Share your TransCode Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.